UnitedHealth Group (NYSE:UNH) Releases FY 2026 Earnings Guidance

Key Points

• UnitedHealth raised FY 2026 adjusted EPS guidance to at least $20.50, above the analyst consensus of approximately $19.86. The increase followed quarterly adjusted EPS of $4.69, which exceeded estimates of about $4.12–$4.14.
• Improved medical-cost performance, stronger margins and operating efficiencies drove a substantial year-over-year profit improvement, while management expects Medicaid margins to bottom in 2026 and recover thereafter.
• Despite a broadly positive analyst consensus—20 Buy ratings and 8 Holds—the stock’s revenue growth remained limited, with quarterly sales slightly down year over year and shares trading near $378.59, below the consensus price target of $462.59.

UnitedHealth Group (NYSE:UNH - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 20.500- for the period, compared to the consensus estimate of 19.860.

UnitedHealth Group Stock Performance

UnitedHealth Group stock traded up $0.07 during mid-day trading on Tuesday, reaching $378.59. The company's stock had a trading volume of 12,633,109 shares, compared to its average volume of 7,378,446. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. UnitedHealth Group has a twelve month low of $255.96 and a twelve month high of $461.62. The business has a 50 day moving average price of $387.44 and a 200-day moving average price of $382.57. The firm has a market cap of $339.82 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 1.43 and a beta of 0.60.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share for the quarter, topping analysts' consensus estimates of $4.14 by $0.55. UnitedHealth Group had a net margin of 3.14% and a return on equity of 16.53%. During the same quarter in the previous year, the business earned $2.59 EPS. The firm's quarterly revenue was down .4% compared to the same quarter last year. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Sell-side analysts predict that UnitedHealth Group will post 19.85 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Shareholders of record on Monday, September 14th were issued a $2.32 dividend. The ex-dividend date of this dividend was Monday, September 14th. This represents a $9.28 dividend on an annualized basis and a yield of 2.5%. UnitedHealth Group's dividend payout ratio (DPR) is currently 59.72%.

Analyst Upgrades and Downgrades

UNH has been the subject of a number of research reports. Wells Fargo & Company lifted their target price on UnitedHealth Group from $397.00 to $485.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Raymond James Financial raised their price target on UnitedHealth Group from $370.00 to $460.00 and gave the stock an "outperform" rating in a report on Tuesday, July 14th. Royal Bank Of Canada boosted their price objective on UnitedHealth Group from $463.00 to $478.00 and gave the company an "outperform" rating in a research report on Friday, July 17th. Argus increased their target price on UnitedHealth Group from $400.00 to $470.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. Finally, Robert W. Baird upgraded UnitedHealth Group from an "underperform" rating to a "neutral" rating and raised their target price for the company from $287.00 to $453.00 in a research note on Thursday, July 16th. Twenty equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, UnitedHealth Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $462.59.

Insiders Place Their Bets

In other news, CEO Patrick Conway sold 1,169 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $390.00, for a total value of $455,910.00. Following the completion of the sale, the chief executive officer directly owned 15,328 shares of the company's stock, valued at approximately $5,977,920. This represents a 7.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.19% of the stock is owned by insiders.

Key UnitedHealth Group News

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Q3 earnings beat expectations: Adjusted earnings were $4.69 per share versus consensus estimates near $4.12–$4.14, while revenue of approximately $112.7 billion also topped forecasts. Operating earnings jumped 52% to $6.6 billion. UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
• Positive Sentiment: Improved medical-cost performance: Lower medical costs, better margins and tighter operating discipline lifted profit substantially from the prior-year quarter. Management said its turnaround strategy, including exiting or reducing unprofitable business, is improving profitability. UNH Tops Q3 Earnings on Lower Medical Costs, Raises 2026 Outlook
• Positive Sentiment: Higher 2026 outlook and constructive 2027 commentary: UnitedHealth raised its 2026 adjusted earnings guidance to at least $20.50 per share, and executives indicated that consensus forecasts for 2027 may be too conservative. Management is targeting 13%–16% long-term earnings growth as operations recover. UnitedHealth Says Wall Street May Be Underestimating Its 2027 Earnings Potential
• Positive Sentiment: Medicaid margin recovery anticipated: Management described 2026 as a likely bottom for core Medicaid margins and expects improvement after that point, supporting the case for stronger earnings beyond 2026. UnitedHealth Calls 2026 the Bottom for Medicaid Margins
• Neutral Sentiment: Technology and efficiency initiatives are progressing: UnitedHealth said artificial-intelligence tools reduced clinical review times by roughly 33%, while Optum continues expanding pharmacy and value-based-care services. These efforts could support margins, but their financial impact remains developing.
• Negative Sentiment: Revenue growth remains limited and investor reaction cooled: Quarterly sales were essentially flat or slightly lower year over year, and Optum Health revenue slipped. Shares reversed part of their early rally, suggesting that investors may have expected an even stronger outlook or were concerned that elevated medical costs and mixed healthcare-sector results remain risks.

About UnitedHealth Group

UnitedHealth Group Incorporated NYSE: UNH is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.